Mien-Chie Hung

Q: What Schools Are Affiliated With Mien-Chie Hung

Mien-Chie Hung is affiliated with the following schools: MD Anderson Cancer Center, China Medical University , National Taiwan University, Brandeis University

Mien-Chie Hung's AcademicInfluence.com Rankings

Mien-Chie Hung

Law

#1193

World Rank

#1523

Historical Rank

Common Law

#15

World Rank

#17

Historical Rank

Jurisprudence

#13

World Rank

#41

Historical Rank

International Law

#104

World Rank

#154

Historical Rank

law Degrees

Mien-Chie Hung

Biology

#1212

World Rank

#2062

Historical Rank

Cell Biology

#65

World Rank

#69

Historical Rank

Biochemistry

#79

World Rank

#105

Historical Rank

Molecular Biology

#211

World Rank

#215

Historical Rank

biology Degrees

Download Badge

Law
Biology

Mien-Chie Hung's Degrees

Doctorate Medicine National Taiwan University

Why Is Mien-Chie Hung Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Mien-Chie Hung is a Taiwanese-born American molecular biologist and cancer researcher. He is a Professor and Chair, Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center in Houston, Texas.

(See a Problem?)

Mien-Chie Hung's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. (2004) (1821)
Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial–mesenchymal transition (2004) (1587)
Requirement for neuregulin receptor erbB2 in neural and cardiac development (1995) (1295)
Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells (2001) (1119)
Nuclear localization of EGF receptor and its potential new role as a transcription factor (2001) (1087)
The neu oncogene encodes an epidermal growth factor receptor-related protein (1986) (1074)
Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185 (1986) (994)
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. (2008) (993)
HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation (2001) (970)
Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. (1997) (897)
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer (2006) (870)
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. (2009) (851)
IκB Kinase Promotes Tumorigenesis through Inhibition of Forkhead FOXO3a (2004) (786)
β-Catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression (2000) (714)
The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines (2010) (655)
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation (2008) (653)
IKKβ Suppression of TSC1 Links Inflammation and Tumor Angiogenesis via the mTOR Pathway (2007) (636)
Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. (2007) (634)
Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. (2013) (611)
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression (2017) (602)
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity (2016) (583)
The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells (2004) (576)
Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. (2004) (535)
The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. (1985) (533)
IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. (2004) (526)
Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. (2005) (522)
Akt-Mediated Phosphorylation of EZH2 Suppresses Methylation of Lysine 27 in Histone H3 (2005) (517)
Erk Associates with and Primes GSK-3β for Its Inactivation Resulting in Upregulation of β-Catenin (2005) (494)
HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. (2000) (491)
Survival of cancer cells is maintained by EGFR independent of its kinase activity. (2008) (460)
Deubiquitination and Stabilization of PD-L1 by CSN5. (2016) (453)
Overexpression of ErbB2 in cancer and ErbB2-targeting strategies (2000) (418)
KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. (2012) (410)
BAP1 links metabolic regulation of ferroptosis to tumor suppression (2018) (407)
Degradation of Mcl-1 by β-TrCP Mediates Glycogen Synthase Kinase 3-Induced Tumor Suppression and Chemosensitization (2006) (401)
lncRNA Directs Cooperative Epigenetic Regulation Downstream of Chemokine Signals (2014) (397)
EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. (2011) (387)
Regulation of tumor angiogenesis by EZH2. (2010) (381)
The LINK-A lncRNA Activates Normoxic HIF1α Signaling in Triple-negative Breast Cancer (2016) (379)
p53 regulates epithelial-mesenchymal transition (EMT) and stem cell properties through modulating miRNAs (2010) (379)
LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker (2012) (376)
TRIM24 links a noncanonical histone signature to breast cancer (2010) (375)
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. (2018) (375)
Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. (2000) (373)
Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. (1998) (368)
HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway* (2000) (368)
Cyclin D1 Is Required for Transformation by Activated Neu and Is Induced through an E2F-Dependent Signaling Pathway (2000) (366)
Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. (2009) (364)
Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1. (2012) (360)
Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. (2008) (350)
CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells (2011) (346)
Improved peak detection and quantification of mass spectrometry data acquired from surface‐enhanced laser desorption and ionization by denoising spectra with the undecimated discrete wavelet transform (2005) (346)
Physiological regulation of Akt activity and stability. (2010) (346)
Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. (2005) (343)
EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2 (2013) (342)
Protein localization in disease and therapy (2011) (341)
ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1 (2014) (337)
Long non-coding RNA MALAT1 suppresses breast cancer metastasis (2018) (335)
The crosstalk of mTOR/S6K1 and Hedgehog pathways. (2012) (333)
PD-L1-Mediated Gasdermin C Expression Switches Apoptosis to Pyroptosis in Cancer Cells and Facilitates Tumor Necrosis (2020) (331)
KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta. (2009) (329)
The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. (2006) (326)
Pharmacological Inactivation of Skp2 SCF Ubiquitin Ligase Restricts Cancer Stem Cell Traits and Cancer Progression (2013) (323)
Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. (2004) (322)
Targeting Mammalian Target of Rapamycin Synergistically Enhances Chemotherapy-Induced Cytotoxicity in Breast Cancer Cells (2004) (316)
Tyrosine phosphorylation controls PCNA function through protein stability (2006) (315)
Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. (1999) (313)
Mechanisms Controlling PD-L1 Expression in Cancer. (2019) (311)
β-catenin interacts with and inhibits NF-κB in human colon and breast cancer (2002) (309)
Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival (2006) (307)
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. (2018) (300)
The role of EZH2 in tumour progression (2011) (300)
Basic science of HER-2/neu: a review. (1999) (298)
Determinants of Rapamycin Sensitivity in Breast Cancer Cells (2004) (294)
Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. (2005) (291)
Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. (1993) (289)
The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and Tumorigenesis (2012) (285)
Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers (2008) (284)
p53 regulates epithelial–mesenchymal transition and stem cell properties through modulating miRNAs (2011) (282)
Regulatable Expression of p21-activated Kinase-1 Promotes Anchorage-independent Growth and Abnormal Organization of Mitotic Spindles in Human Epithelial Breast Cancer Cells* (2000) (281)
Interaction between the Adhesion Receptor, CD44, and the Oncogene Product, p185 HER2 , Promotes Human Ovarian Tumor Cell Activation* (1997) (266)
P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells (2004) (253)
Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. (1989) (249)
A new mutational AKTivation in the PI3K pathway. (2007) (245)
Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth (2018) (239)
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion (2018) (239)
Long non-coding RNAs: versatile master regulators of gene expression and crucial players in cancer. (2012) (238)
Characterization of a Novel Tripartite Nuclear Localization Sequence in the EGFR Family* (2007) (238)
Nuclear‐cytoplasmic transport of EGFR involves receptor endocytosis, importin β1 and CRM1 (2006) (237)
Regulation and Role of EZH2 in Cancer (2014) (237)
p53 regulates epithelial–mesenchymal transition and stem cell properties through modulating miRNAs (2011) (235)
A New Fork for Clinical Application: Targeting Forkhead Transcription Factors in Cancer (2009) (235)
Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. (1996) (233)
The role of the VEGF-C/VEGFR-3 axis in cancer progression (2006) (232)
EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization (2006) (231)
Endosomal Transport of ErbB-2: Mechanism for Nuclear Entry of the Cell Surface Receptor (2005) (230)
Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. (2010) (230)
Quality control and peak finding for proteomics data collected from nipple aspirate fluid by surface-enhanced laser desorption and ionization. (2003) (229)
Vimentin Is a Novel Anti-Cancer Therapeutic Target; Insights from In Vitro and In Vivo Mice Xenograft Studies (2010) (228)
A perspective on anti-EGFR therapies targeting triple-negative breast cancer. (2016) (226)
c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. (1994) (225)
Phosphorylation of CBP by IKKα Promotes Cell Growth by Switching the Binding Preference of CBP from p53 to NF-κB (2007) (220)
RAC1 activation mediates Twist1-induced cancer cell migration (2012) (220)
A ROR1-HER3-LncRNA signaling axis modulates the Hippo-YAP pathway to regulate bone metastasis (2017) (214)
Nuclear trafficking of the epidermal growth factor receptor family membrane proteins (2010) (211)
Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties. (2014) (207)
Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis (2010) (206)
Oncogenic LncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression (2019) (204)
Vimentin is a novel AKT1 target mediating motility and invasion (2010) (203)
MDM2 Promotes Cell Motility and Invasiveness by Regulating E-Cadherin Degradation (2006) (201)
Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. (2001) (200)
Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation. (2014) (194)
14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. (2009) (194)
Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation (2011) (193)
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer (2016) (192)
Co‐regulation of B‐Myb expression by E2F1 and EGF receptor (2006) (190)
Mesenchymal stem cells promote growth and angiogenesis of tumors in mice (2013) (186)
Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade (2019) (183)
The Ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis (2000) (183)
The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer (2015) (182)
Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial–mesenchymal transition (2007) (182)
Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. (2019) (182)
Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. (1999) (181)
Hyaluronan Promotes CD44v3-Vav2 Interaction with Grb2-p185HER2 and Induces Rac1 and Ras Signaling during Ovarian Tumor Cell Migration and Growth* (2001) (180)
Nuclear Translocation of the Epidermal Growth Factor Receptor Family Membrane Tyrosine Kinase Receptors (2009) (178)
Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer. (2007) (178)
Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. (2008) (177)
Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin. (1995) (176)
14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. (2009) (175)
EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. (2016) (173)
Nonviral vectors for gene therapy (1999) (173)
Molecular predictors of response to trastuzumab and lapatinib in breast cancer (2010) (172)
Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors (2016) (172)
P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. (2004) (171)
Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. (2009) (168)
Nuclear Translocation of Epidermal Growth Factor Receptor by Akt-dependent Phosphorylation Enhances Breast Cancer-resistant Protein Expression in Gefitinib-resistant Cells* (2011) (168)
Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. (2009) (168)
Phosphorylation/Cytoplasmic Localization of p21Cip1/WAF1 Is Associated with HER2/neu Overexpression and Provides a Novel Combination Predictor for Poor Prognosis in Breast Cancer Patients (2004) (168)
Krüppel-like factor 8 induces epithelial to mesenchymal transition and epithelial cell invasion. (2007) (168)
Modeling Familial Cancer with Induced Pluripotent Stem Cells (2015) (167)
GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. (2008) (163)
Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. (1997) (161)
beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. (2002) (161)
IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. (2019) (161)
The LINK-A lncRNA interacts with PI(3,4,5)P3 to hyperactivate AKT and confer resistance to AKT inhibitors (2017) (160)
Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth. (2005) (160)
Xenoestrogen-induced regulation of EZH2 and histone methylation via estrogen receptor signaling to PI3K/AKT. (2010) (158)
Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer (2009) (158)
Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. (2011) (156)
Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. (1999) (156)
Expression profile of tyrosine kinases in breast cancer. (2002) (155)
HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. (2000) (152)
A novel splice variant of HER2 with increased transformation activity (1998) (152)
High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma (2000) (150)
Sustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF-β-dependent cancer metastasis. (2014) (150)
KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling. (2013) (150)
Mesenchymal stem cells promote formation of colorectal tumors in mice. (2011) (148)
Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy. (2018) (144)
JAK2-binding long noncoding RNA promotes breast cancer brain metastasis (2017) (143)
14-3-3ζ turns TGF-β's function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2. (2015) (142)
Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy (2021) (140)
Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor family (2012) (140)
Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. (2010) (140)
Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. (2002) (138)
Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. (1990) (136)
Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol (1998) (135)
Dysregulation of MicroRNAs in cancer (2012) (135)
Nuclear localization of p185neu tyrosine kinase and its association with transcriptional transactivation. (1994) (134)
Regulation of embryonic and induced pluripotency by aurora kinase-p53 signaling. (2012) (134)
Molecular cloning of the neu gene: absence of gross structural alteration in oncogenic alleles. (1986) (134)
Adenovirus-mediated overexpression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53. (1997) (133)
Role of erbB2 in breast cancer chemosensitivity. (2000) (132)
APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. (2011) (131)
Overexpression of the c‐erbB‐2/neu–encoded p185 protein in primary lung cancer (1992) (131)
Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB. (2007) (129)
Oncogenic Signals of HER-2/neu in Regulating the Stability of the Cyclin-dependent Kinase Inhibitor p27* (2000) (129)
Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. (1996) (128)
Independent control elements that determine yolk protein gene expression in alternative Drosophila tissues. (1985) (127)
The Translocon Sec61β Localized in the Inner Nuclear Membrane Transports Membrane-embedded EGF Receptor to the Nucleus* (2010) (125)
Dysregulation of cellular signaling by HER2/neu in breast cancer. (2003) (125)
Induction of Akt activity by chemotherapy confers acquired resistance. (2009) (124)
COPI-mediated retrograde trafficking from the Golgi to the ER regulates EGFR nuclear transport. (2010) (122)
p53 Acetylation Is Crucial for Its Transcription-independent Proapoptotic Functions* (2009) (122)
Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties (1998) (121)
Advances in Targeting Human Epidermal Growth Factor Receptor-2 Signaling for Cancer Therapy (2006) (121)
Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. (2001) (121)
miR-100 Induces Epithelial-Mesenchymal Transition but Suppresses Tumorigenesis, Migration and Invasion (2014) (120)
Inhibition of Nuclear Factor-κB Activity Is Involved in E1A-mediated Sensitization of Radiation-induced Apoptosis* (1997) (119)
Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. (2002) (119)
Cancer-specific activation of the survivin promoter and its potential use in gene therapy (2004) (118)
Deubiquitination and stabilization of PTEN by USP13 (2013) (117)
The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis (2020) (117)
Akt activation by estrogen in estrogen receptor-negative breast cancer cells. (2001) (117)
All Roads Lead to mTOR: Integrating Inflammation and Tumor Angiogenesis (2007) (116)
Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. (2005) (115)
Crystal structure of the human FOXO3a-DBD/DNA complex suggests the effects of post-translational modification (2007) (115)
Aurora Kinase A Promotes Ovarian Tumorigenesis through Dysregulation of the Cell Cycle and Suppression of BRCA2 (2010) (115)
Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. (2008) (114)
AIM2 suppresses human breast cancer cell proliferation in vitro and mammary tumor growth in a mouse model (2006) (114)
Wnt, Hedgehog, and Snail: Sister Pathways That Control by GSK-3beta and beta-Trcp in the Regulation of Metastasis (2005) (114)
Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function. (2018) (114)
Advances in Targeting IKK and IKK-Related Kinases for Cancer Therapy (2008) (114)
Amplification and expression of the c‐erb B‐2/neu proto‐oncogene in human bladder cancer (1990) (113)
Palmitoylation stabilizes PD-L1 to promote breast tumor growth (2018) (112)
Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor. (1992) (112)
Amplification and rearrangement of c-erb B proto-oncogenes in cancer of human female genital tract. (1989) (112)
Regulation of the Activity of p38 Mitogen-Activated Protein Kinase by Akt in Cancer and Adenoviral Protein E1A-Mediated Sensitization to Apoptosis (2003) (112)
Signaling cross-talk in the resistance to HER family receptor targeted therapy (2014) (112)
Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells. (1991) (110)
Recombinant PML adenovirus suppresses growth and tumorigenicity of human breast cancer cells by inducing G1 cell cycle arrest and apoptosis (1998) (110)
FOXC1 Activates Smoothened-Independent Hedgehog Signaling in Basal-like Breast Cancer. (2015) (109)
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer (2009) (109)
Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry (2004) (109)
E1A Sensitizes Cells to Tumor Necrosis Factor-induced Apoptosis through Inhibition of IκB Kinases and Nuclear Factor κB Activities* (1999) (108)
A hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase/Akt in HER2 overexpressing cells. (2005) (107)
ERK Activation Globally Downregulates miRNAs through Phosphorylating Exportin-5. (2016) (107)
Targeting HER2: recent developments and future directions for breast cancer patients. (2001) (107)
Linking genomic reorganization to tumor initiation via the giant cell cycle (2016) (107)
E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. (2000) (105)
Suppression of tumorigenicity of breast cancer cells by an epithelial cell adhesion molecule (C-CAM1): the adhesion and growth suppression are mediated by different domains (1997) (105)
MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1. (2019) (105)
Block-Cell-Printing for live single-cell printing (2014) (104)
RNA helicase A is a DNA-binding partner for EGFR-mediated transcriptional activation in the nucleus (2010) (104)
Preferential DNA damage and poor repair determine ras gene mutational hotspot in human cancer. (2002) (104)
Breast cancer brain metastases (2007) (104)
A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer (2016) (103)
Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A (1997) (102)
PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response. (2015) (101)
MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol (2013) (101)
Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells (2010) (100)
Nuclear EGFR is required for cisplatin resistance and DNA repair. (2009) (100)
Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. (1995) (100)
Actin cytoskeleton remodeling drives epithelial‐mesenchymal transition for hepatoma invasion and metastasis in mice (2018) (98)
Long noncoding RNA MALAT1 suppresses breast cancer metastasis (2018) (98)
Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells. (1995) (98)
Interplay between arginine methylation and ubiquitylation regulates KLF4-mediated genome stability and carcinogenesis (2015) (97)
Adenovirus type 5 E1A gene products act as transformation suppressors of the neu oncogene (1991) (97)
Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. (2005) (96)
HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. (1995) (96)
Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications (2018) (95)
A UBE2O-AMPKα2 Axis that Promotes Tumor Initiation and Progression Offers Opportunities for Therapy. (2017) (95)
Sequence and structure conservation in yolk proteins and their genes. (1983) (94)
The roles of EZH2 in cell lineage commitment. (2011) (93)
Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products. (1992) (93)
Targeted expression of miR-34a using the T-VISA system suppresses breast cancer cell growth and invasion. (2012) (92)
Systemic tumor suppression by the proapoptotic gene bik. (2002) (92)
Novel targets of Akt, p21(Cipl/WAF1), and MDM2. (2002) (92)
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers (2017) (91)
IKKα activation of NOTCH links tumorigenesis via FOXA2 suppression. (2012) (89)
ARD1 Stabilization of TSC2 Suppresses Tumorigenesis Through the mTOR Signaling Pathway (2010) (89)
STK15/Aurora‐A expression in primary breast tumors is correlated with nuclear grade but not with prognosis (2004) (88)
The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer* (1997) (87)
Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype (2016) (86)
Aberrant expression of the c-erbB-2/neu protooncogene in ovarian cancer. (1992) (85)
MicroRNA-205 signaling regulates mammary stem cell fate and tumorigenesis. (2014) (85)
Smurf2-mediated degradation of EZH2 enhances neuron differentiation and improves functional recovery after ischaemic stroke (2013) (85)
Targeting Tyrosine Phosphorylation of PCNA Inhibits Prostate Cancer Growth (2011) (84)
Epigenetic regulation of the miR142-3p/interleukin-6 circuit in glioblastoma. (2013) (84)
The Adaptor Protein CARD9 Protects against Colon Cancer by Restricting Mycobiota‐Mediated Expansion of Myeloid‐Derived Suppressor Cells (2018) (84)
ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis. (2020) (83)
HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model. (1995) (83)
Adenovirus 5 E1A-mediated tumor suppression associated with E1A-mediated apoptosis in vivo (1998) (83)
Crossregulation of NF‐κB by the APC/GSK‐3β/β‐catenin pathway (2004) (82)
MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer (2014) (82)
Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis (2002) (82)
CARMA3 is crucial for EGFR-Induced activation of NF-κB and tumor progression. (2011) (81)
The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. (2005) (80)
Beyond NF-κB activation: nuclear functions of IκB kinase α (2013) (80)
Unfolded Protein Response Is Required in nu/nu Mice Microvasculature for Treating Breast Tumor with Tunicamycin* (2011) (80)
Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. (2007) (79)
Membrane-bound Trafficking Regulates Nuclear Transport of Integral Epidermal Growth Factor Receptor (EGFR) and ErbB-2* (2012) (79)
BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. (2011) (79)
Oral cancer progression and c-erbB-2/neu proto-oncogene expression. (1992) (79)
Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing Cells (2011) (79)
Her2/neu induces all-transretinoic acid (ATRA) resistance in breast cancer cells (2002) (78)
Crosstalk between Protease-activated Receptor 1 and Platelet-activating Factor Receptor Regulates Melanoma Cell Adhesion Molecule (MCAM/MUC18) Expression and Melanoma Metastasis* (2009) (78)
Strategies to target HER2/neu overexpression for cancer therapy. (2003) (77)
HER-2/neu-targeting gene therapy--a review. (1995) (77)
Cellular models of macrophage tumoricidal effector mechanisms in vitro. Characterization of cytolytic responses to tumor necrosis factor and nitric oxide pathways in vitro. (1991) (77)
Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing. (2018) (76)
JARID1D Is a Suppressor and Prognostic Marker of Prostate Cancer Invasion and Metastasis. (2016) (75)
Cancer-specific gene therapy. (2005) (75)
Loss of aurora A/STK15/BTAK overexpression correlates with transition of in situ to invasive ductal carcinoma of the breast. (2003) (75)
Caspase-Independent Cell Death Is Involved in the Negative Effect of EGF Receptor Inhibitors on Cisplatin in Non–Small Cell Lung Cancer Cells (2013) (75)
Deep and high-resolution three-dimensional tracking of single particles using nonlinear and multiplexed illumination (2015) (74)
Nuclear ErbB2 enhances translation and cell growth by activating transcription of ribosomal RNA genes. (2011) (74)
Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim. (2010) (74)
EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer (2017) (73)
Expression of an altered epidermal growth factor receptor by human glioblastoma cells. (1988) (73)
Crystal structure of the human FOXO3a-DBD/DNA complex suggests the effects of post-translational modification. (2008) (72)
A hypoxia-responsive TRAF6–ATM–H2AX signalling axis promotes HIF1α activation, tumorigenesis and metastasis (2016) (72)
Deciphering the role of forkhead transcription factors in cancer therapy. (2011) (72)
E1A sensitizes HER2/neu-overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs. (2001) (72)
ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway. (2014) (71)
The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and Tumorigenesis (2012) (71)
Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells (2006) (70)
c-myc reverses neu-induced transformed morphology by transcriptional repression (1991) (70)
Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer. (2010) (69)
IKKbeta suppression of TSC1 function links the mTOR pathway with insulin resistance. (2008) (69)
HER2 overexpression and cancer targeting. (2001) (69)
Electrospinning of silica nanochannels for single molecule detection (2006) (68)
Survival of Cancer Stem Cells under Hypoxia and Serum Depletion via Decrease in PP2A Activity and Activation of p38-MAPKAPK2-Hsp27 (2012) (68)
Erythropoietin Stimulates Tumor Growth via EphB4. (2015) (67)
High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma (2015) (67)
Axl-Gas6 Interaction Counteracts E1A-Mediated Cell Growth Suppression and Proapoptotic Activity (1999) (67)
A multicenter phase II study of tgDCC‐E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma (2002) (67)
EGFR modulates DNA synthesis and repair through Tyr phosphorylation of histone H4. (2014) (67)
IKKα restoration via EZH2 suppression induces nasopharyngeal carcinoma differentiation (2014) (67)
CXCR4 expression in early breast cancer and risk of distant recurrence. (2009) (66)
Repressed expression of the HER-2/c-erbB-2 proto-oncogene by the adenovirus E1a gene products. (1991) (66)
Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases (2015) (65)
JNK1 negatively controls anti-fungal innate immunity by suppressing CD23 expression (2017) (65)
Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma. (2008) (65)
Rapamycin Regulates Stearoyl CoA Desaturase 1 Expression in Breast Cancer (2010) (65)
A Tumorigenic Factor Interactome Connected through Tumor Suppressor MicroRNA-198 in Human Pancreatic Cancer (2013) (64)
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics (2022) (64)
AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation. (2016) (64)
Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells (1999) (64)
NF-κB signaling mediates the induction of MTA1 by hepatitis B virus transactivator protein HBx (2010) (63)
Automated electrorotation to reveal dielectric variations related to HER-2/neu overexpression in MCF-7 sublines. (2002) (63)
The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis (2020) (63)
External control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator (2002) (63)
TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase. (2013) (63)
Rapamycin regulates the phosphorylation of rictor. (2007) (62)
Signaling intricacies take center stage in cancer cells. (2005) (62)
Mitosis-specific Negative Regulation of Epidermal Growth Factor Receptor, Triggered by a Decrease in Ligand Binding and Dimerization, Can Be Overcome by Overexpression of Receptor* (1997) (61)
Involvement of Co-activator p300 in the Transcriptional Regulation of the HER-2/neu Gene* (1997) (61)
Antitumor agents. 272. Structure-activity relationships and in vivo selective anti-breast cancer activity of novel neo-tanshinlactone analogues. (2010) (61)
Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma (2017) (61)
Downregulation of microRNA miR-520h by E1A contributes to anticancer activity. (2010) (60)
EZH2: a pivotal regulator in controlling cell differentiation. (2012) (60)
Brk/PTK6 Sustains Activated EGFR Signaling through Inhibiting EGFR Degradation and Transactivating EGFR (2011) (59)
Controlled extracellular matrix degradation in breast cancer tumors improves therapy by trastuzumab. (2011) (59)
Molecular mechanisms and functions of pyroptosis in inflammation and antitumor immunity. (2021) (59)
Targeting the EGFR/PCNA Signaling Suppresses Tumor Growth of Triple-Negative Breast Cancer Cells with Cell-Penetrating PCNA Peptides (2013) (59)
Epidermal growth factor receptor potentiates MCM7-mediated DNA replication through tyrosine phosphorylation of Lyn kinase in human cancers. (2013) (58)
Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death (2019) (58)
TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. (2021) (58)
Enhancement of Bik antitumor effect by Bik mutants. (2003) (57)
Multiple cis- and trans-acting elements involved in regulation of the neu gene (1990) (57)
EZH2 Regulates Neuronal Differentiation of Mesenchymal Stem Cells through PIP5K1C-dependent Calcium Signaling* (2011) (57)
Myocyte Enhancer Factor-2 Interacting Transcriptional Repressor (MITR) Is a Switch That Promotes Osteogenesis and Inhibits Adipogenesis of Mesenchymal Stem Cells by Inactivating Peroxisome Proliferator-activated Receptor γ-2* (2011) (57)
ErbB2-Mediated Src and Signal Transducer and Activator of Transcription 3 Activation Leads to Transcriptional Up-Regulation of p21Cip1 and Chemoresistance in Breast Cancer Cells (2009) (57)
DOC-2/hDab-2 inhibits ILK activity and induces anoikis in breast cancer cells through an Akt-independent pathway (2001) (56)
Dominant-negative Mutants of Grb2 Induced Reversal of the Transformed Phenotypes Caused by the Point Mutation-activated Rat HER-2/Neu(*) (1995) (56)
beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma. (2003) (56)
p27 Kip1 inhibits HER2/neu-mediated cell growth and tumorigenesis (2001) (55)
Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. (2021) (55)
Regulation of Ubiquitination-Mediated Protein Degradation by Survival Kinases in Cancer (2011) (54)
Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. (2002) (54)
Correlation of p27 protein expression with HER‐2/neu expression in breast cancer (2001) (54)
Amplification of the proto-neu oncogene facilitates oncogenic activation by a single point mutation. (1989) (54)
Syntaxin 6-mediated Golgi translocation plays an important role in nuclear functions of EGFR through microtubule-dependent trafficking (2014) (53)
Colon cancer stem cells resist antiangiogenesis therapy-induced apoptosis. (2013) (53)
Signaling-mediated regulation of MicroRNA processing. (2015) (53)
HIF-1&agr; promotes autophagic proteolysis of Dicer and enhances tumor metastasis (2017) (53)
Inhibition of cancer cell growth by BRCA2. (2002) (53)
Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer (2016) (53)
Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer. (2000) (52)
Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity (2020) (52)
Expression of Long Noncoding RNA YIYA Promotes Glycolysis in Breast Cancer. (2018) (52)
Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer. (2014) (52)
Structural and Functional Impacts of ER Coactivator Sequential Recruitment. (2017) (51)
A Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer. (1998) (51)
SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway (2020) (51)
A New Role of Protein Phosphatase 2A in Adenoviral E1A Protein-Mediated Sensitization to Anticancer Drug-Induced Apoptosis in Human Breast Cancer Cells (2004) (51)
Adenovirus E1A expression enhances the sensitivity of an ovarian cancer cell line to multiple cytotoxic agents through an apoptotic mechanism. (1997) (50)
Assessing metastatic potential of breast cancer cells based on EGFR dynamics (2019) (50)
Nuclear EGFR Suppresses Ribonuclease Activity of Polynucleotide Phosphorylase through DNAPK-mediated Phosphorylation at Serine 776* (2012) (50)
Tid1, CHIP and ErbB2 interactions and their prognostic implications for breast cancer patients (2011) (50)
The sequence of the Drosophila melanogaster gene for yolk protein 1. (1981) (50)
Tankyrase disrupts metabolic homeostasis and promotes tumorigenesis by inhibiting LKB1-AMPK signalling (2019) (49)
Metastasis regulation by PPARD expression in cancer cells. (2017) (49)
Altered Expression and Splicing of ESRP1 in Malignant Melanoma Correlates with Epithelial–Mesenchymal Status and Tumor-Associated Immune Cytolytic Activity (2016) (48)
Stabilization of ERK-Phosphorylated METTL3 by USP5 Increases m6A Methylation. (2020) (48)
Recent developments in breast cancer therapy. (1999) (48)
PTEN-induced partial epithelial-mesenchymal transition drives diabetic kidney disease (2019) (48)
Interaction of Proliferation Cell Nuclear Antigen (PCNA) with c-Abl in Cell Proliferation and Response to DNA Damages in Breast Cancer (2012) (47)
Loss of FBP 1 by Snail-Mediated Repression Provides Metabolic Advantages in Basal-Like Breast Cancer (2017) (47)
Nanoparticle Delivery of miR-34a Eradicates Long-term-cultured Breast Cancer Stem Cells via Targeting C22ORF28 Directly (2017) (46)
p202, an interferon-inducible protein, mediates multiple antitumor activities in human pancreatic cancer xenograft models. (2001) (46)
Adenovirus type 5 E1A sensitizes hepatocellular carcinoma cells to gemcitabine. (2003) (46)
Mechanisms of synthetic serine protease inhibitor (FUT‐175)‐mediated cell death (2007) (45)
TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer (2020) (45)
ASPH-notch Axis guided Exosomal delivery of Prometastatic Secretome renders breast Cancer multi-organ metastasis (2019) (45)
PTEN self-regulates through USP11 via the PI3K-FOXO pathway to stabilize tumor suppression (2019) (45)
Non-viral vectors for gene therapy (2005) (45)
Role for the double-stranded RNA activated protein kinase PKR in E2F-1-induced apoptosis (2002) (44)
The ZNF304-integrin axis protects against anoikis in cancer (2015) (44)
CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer (2019) (44)
Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer. (2018) (44)
Cancer Targeted Gene Therapy of BikDD Inhibits Orthotopic Lung Cancer Growth and Improves Long-term Survival (2009) (44)
Cross-reactivity of C219 anti-p170(mdr-1) antibody with p185(c-erbB2) in breast cancer cells: cautions on evaluating p170(mdr-1) (1997) (44)
Nuclear translocation of the pro‐apoptotic Bcl‐2 family member Bok induces apoptosis (2005) (43)
Non-canonical signaling mode of the epidermal growth factor receptor family. (2015) (43)
b-Catenin , a novel prognostic marker for breast cancer : Its roles in cyclin D 1 expression and cancer progression (2000) (43)
Further evidence for expression and function of the VEGF-C/VEGFR-3 axis in cancer cells. (2008) (43)
Antitumor agents. 258. Syntheses and evaluation of dietary antioxidant--taxoid conjugates as novel cytotoxic agents. (2007) (43)
Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer. (2018) (42)
Tannic acid suppresses SARS-CoV-2 as a dual inhibitor of the viral main protease and the cellular TMPRSS2 protease. (2020) (42)
Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer (2004) (42)
E1A sensitizes cells to tumor necrosis factor-induced apoptosis through inhibition of IkappaB kinases and nuclear factor kappaB activities. (1999) (42)
Structural basis of SARS-CoV-2 main protease inhibition by a broad-spectrum anti-coronaviral drug. (2020) (41)
S6K1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer. (2014) (41)
Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. (2018) (41)
Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells (2000) (40)
FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization. (2011) (40)
Cytoplasmic/Nuclear Shuttling and Tumor Progression (2005) (40)
EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma. (2018) (40)
Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer (2021) (40)
Blocking immunosuppressive neutrophils deters pY696-EZH2–driven brain metastases (2020) (40)
Tumor suppression and sensitization to tumor necrosis factor alpha-induced apoptosis by an interferon-inducible protein, p202, in breast cancer cells. (2000) (40)
Transcript maps of Drosophila yolk protein genes. (1982) (40)
EGFR–SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors (2013) (40)
Aurora A kinase activates YAP signaling in triple-negative breast cancer (2017) (39)
Inhibition of angiogenesis and induction of apoptosis are involved in E1A-mediated bystander effect and tumor suppression. (2000) (39)
SRC-3 coactivator regulates cell resistance to cytotoxic stress via TRAF4-mediated p53 destabilization. (2013) (39)
Pharmacological suppression of B7-H4 glycosylation restores antitumor immunity in immune-cold breast cancers. (2020) (39)
Suspension survival mediated by PP2A-STAT3-Col XVII determines tumour initiation and metastasis in cancer stem cells (2016) (39)
Selective Activation of Ceruloplasmin Promoter in Ovarian Tumors (2004) (39)
The suppression of colon cancer cell growth in nude mice by targetingβ-catenin/TCF pathway (2002) (39)
E1A inhibition of radiation-induced NF-κB activity through suppression of IKK activity and IκB degradation, independent of Akt activation (2001) (38)
The human ARHI tumor suppressor gene inhibits lactation and growth in transgenic mice. (2000) (38)
Changes in BRCA2 expression during progression of the cell cycle. (1997) (38)
Upregulation of IKKα/IKKβ by integrin-linked kinase is required for HER2/neu-induced NF-κB antiapoptotic pathway (2004) (38)
Adenoviral E1A Targets Mdm4 to Stabilize Tumor Suppressor p53 (2004) (38)
Inefficient proteasomal‐degradation pathway stabilizes AP‐2α and activates HER‐2/neu gene in breast cancer (2006) (38)
Enhancer of Zeste Homolog 2 and Histone Deacetylase 9c Regulate Age‐Dependent Mesenchymal Stem Cell Differentiation into Osteoblasts and Adipocytes (2016) (38)
Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors. (2011) (37)
ErbB-2 induces the cyclin D1 gene in prostate epithelial cells in vitro and in vivo. (2007) (37)
p66Shc isoform down-regulated and not required for HER-2/neu signaling pathway in human breast cancer cell lines with HER-2/neu overexpression. (1996) (37)
Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers. (2015) (37)
Reexpression of neu-encoded oncoprotein counteracts the tumor-suppressing but not the metastasis-suppressing function of E1A. (1993) (37)
HER2/neu in the management of invasive breast cancer. (2002) (37)
LncRNA H19 Alleviates Muscular Dystrophy Through Stabilizing Dystrophin (2020) (36)
Reduced growth rate and transformation phenotype of the prostate cancer cells by an interferon-inducible protein, p202 (1999) (36)
Extracellular PKM2 induces cancer proliferation by activating the EGFR signaling pathway. (2016) (36)
Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer (2015) (36)
Tyrosine 370 phosphorylation of ATM positively regulates DNA damage response (2015) (36)
Association between ductal fluid proteomic expression profiles and the presence of lymph node metastases in women with breast cancer. (2004) (36)
Cloning and characterization of the mouse neu promoter. (1992) (35)
LncRNAs-directed PTEN enzymatic switch governs epithelial–mesenchymal transition (2019) (35)
A novel hTERT promoter–driven E1A therapeutic for ovarian cancer (2009) (35)
The retinoblastoma gene product suppresses neu oncogene-induced transformation via transcriptional repression of neu. (1992) (35)
miRNA-7/21/107 contribute to HBx-induced hepatocellular carcinoma progression through suppression of maspin (2015) (35)
The NH(2)-terminal and conserved region 2 domains of adenovirus E1A mediate two distinct mechanisms of tumor suppression. (2002) (34)
Expanding the arsenal: Metformin for the treatment of triple-negative breast cancer? (2009) (34)
Upregulation of IKKalpha/IKKbeta by integrin-linked kinase is required for HER2/neu-induced NF-kappaB antiapoptotic pathway. (2004) (34)
Tyrosine phosphorylation of Shc proteins and formation of Shc/Grb2 complex correlate to the transformation of NIH3T3 cells mediated by the point-mutation activated neu. (1995) (34)
An attenuated Salmonella oral DNA vaccine prevents the growth of hepatocellular carcinoma and colon cancer that express α-fetoprotein (2006) (34)
Beyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapy. (2013) (34)
Inhibition of Type I Insulin-Like Growth Factor Receptor Signaling Attenuates the Development of Breast Cancer Brain Metastasis (2013) (34)
Targeted hepatocellular carcinoma proapoptotic BikDD gene therapy (2011) (33)
GSK3β inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers (2016) (33)
The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells. (2011) (33)
Differental amplification of the TGF-α gene in human gliomas (1990) (33)
Clinical Biology of Esophageal Adenocarcinoma after Surgery Is Influenced by Nuclear Factor-κB Expression (2007) (32)
Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation. (2016) (32)
Different restriction enzyme-generated sticky DNA ends can be joined in vitro. (1984) (32)
HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer (2015) (32)
Inhibition of nuclear factor-kappaB activity is involved in E1A-mediated sensitization of radiation-induced apoptosis. (1997) (31)
The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells (2017) (31)
Upregulation of lactate dehydrogenase a by 14-3-3ζ leads to increased glycolysis critical for breast cancer initiation and progression (2016) (31)
TIE2-mediated tyrosine phosphorylation of H4 regulates DNA damage response by recruiting ABL1 (2016) (30)
Linear ubiquitination of cFLIP induced by LUBAC contributes to TNFα-induced apoptosis (2018) (30)
Antitumor agents 270. Novel substituted 6-phenyl-4H-furo[3,2-c]pyran-4-one derivatives as potent and highly selective anti-breast cancer agents. (2010) (30)
Lapatinib-Mediated Cyclooxygenase-2 Expression via Epidermal Growth Factor Receptor/HuR Interaction Enhances the Aggressiveness of Triple-Negative Breast Cancer Cells (2013) (30)
Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. (2010) (30)
Role of IκB kinase in tumorigenesis (2005) (30)
ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer. (2018) (29)
Up-regulation of urokinase-type plasminogen activator expression by the HER2/neu proto-oncogene. (1995) (29)
Cytoplasmic expression of p21CIP1/WAF1 is correlated with IKKbeta overexpression in human breast cancers. (2006) (29)
Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non–Small Cell Lung Cancer (2018) (29)
Targeting the IKKβ/mTOR/VEGF Signaling Pathway as a Potential Therapeutic Strategy for Obesity-Related Breast Cancer (2012) (28)
Direct sequencing analysis of transmembrane region of human neu gene by polymerase chain reaction (2006) (28)
miR326 maturation is crucial for VEGF-C-driven cortactin expression and esophageal cancer progression. (2014) (28)
Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation (2010) (28)
Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer (2016) (28)
Development and validation of a radiopathomics model to predict pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a multicentre observational study. (2022) (28)
Identification and characterization of a novel enhancer for the rat neu promoter (1991) (28)
Epidermal growth factor receptor expression and function control cytotoxic responsiveness to tumor necrosis factor in ME-180 squamous carcinoma cells. (1993) (28)
Activation of Aurora A kinase increases YAP stability via blockage of autophagy (2019) (28)
Suppression of pancreatic tumor progression by systemic delivery of a pancreatic-cancer-specific promoter driven Bik mutant. (2006) (28)
Mapping of adenovirus 5 E1A domains responsible for suppression of neu-mediated transformation via transcriptional repression of neu (1997) (28)
Control of Gene Expression (1974) (27)
The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PD‐L1 (2020) (27)
The erbB2 gene as a cancer therapeutic target and the tumor- and metastasis-suppressing function of E1A (1998) (27)
Inhibition of intratracheal lung cancer development by systemic delivery of E1A. (1996) (27)
In Vivo Targeting of ADAM9 Gene Expression Using Lentivirus-Delivered shRNA Suppresses Prostate Cancer Growth by Regulating REG4 Dependent Cell Cycle Progression (2013) (27)
Argininosuccinate synthetase 1 (ASS1) is a common metabolic marker of chemosensitivity for targeted arginine- and glutamine-starvation therapy. (2017) (27)
Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer. (2020) (27)
Human pro-tumor necrosis factor: molecular determinants of membrane translocation, sorting, and maturation (1995) (26)
Arrest-defective-1 protein (ARD1): tumor suppressor or oncoprotein? (2010) (26)
EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer (2012) (26)
Hepatitis B virus X protein induces IKKα nuclear translocation via Akt‐Dependent phosphorylation to promote the motility of hepatocarcinoma cells (2012) (26)
Transcriptional targeting of the HER-2/neu oncogene. (2000) (26)
Negative regulation of the neu promoter by the SV40 large T antigen. (1993) (25)
Role of aromatic residues in the structure-function relationship of alpha-bungarotoxin. (1982) (25)
Role of IkappaB kinase in tumorigenesis. (2005) (25)
Antitumor activity of an Ets protein, PEA3, in breast cancer cell lines MDA‐MB‐361DYT2 and BT474M1 (2006) (25)
TNFalpha induces HIF-1alpha expression through activation of IKKbeta. (2009) (25)
Targeted Expression of BikDD Eliminates Breast Cancer with Virtually No Toxicity in Noninvasive Imaging Models (2012) (25)
Cell cycle-dependent regulation of p185neu: a relationship between disruption of this regulation and transformation. (1995) (25)
A noncoding RNA modulator potentiates phenylalanine metabolism in mice (2021) (24)
Segmentation of 3D Trajectories Acquired by TSUNAMI Microscope: An Application to EGFR Trafficking. (2016) (24)
Developmental control of Drosophila yolk protein 1 gene by cis-acting DNA elements. (1985) (24)
The Hippo coactivator YAP 1 mediates EGFR overexpression and confers chemo-resistance in esophageal cancer (2015) (24)
Severe Hepatitis Promotes Hepatocellular Carcinoma Recurrence via NF-κB Pathway-Mediated Epithelial–Mesenchymal Transition after Resection (2015) (24)
Activation of Keap1/Nrf2 signaling pathway by nuclear epidermal growth factor receptor in cancer cells. (2014) (24)
Mutant SV40 large T antigen as a therapeutic agent for HER-2/neu-overexpressing ovarian cancer. (1996) (24)
Characterization of BRCA2: temperature sensitivity of detection and cell-cycle regulated expression (1998) (24)
Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma (2018) (24)
The effects of Photofrin-mediated photodynamic therapy on the modulation of EGFR in esophageal squamous cell carcinoma cells (2013) (23)
Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model. (2005) (23)
Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinoma (2020) (23)
Inhibition of VEGF165/VEGFR2-dependent signaling by LECT2 suppresses hepatocellular carcinoma angiogenesis (2016) (23)
Novel approaches for chemosensitization of breast cancer cells: the E1A story. (2007) (23)
Molecular mechanisms in Barrett's metaplasia and its progression. (2007) (23)
Transcription-coupled DNA Repair Is Genomic Context-dependent* (2002) (23)
Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment (2020) (22)
Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance (2021) (22)
Negative autoregulation of the neu gene is mediated by a novel enhancer (1992) (22)
A Positive TGF-β/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer12 (2016) (22)
Effect of glucocorticoids on oncogene transformed NIH3T3 cells. (1990) (22)
Aberrant Expression of proPTPRN2 in Cancer Cells Confers Resistance to Apoptosis. (2015) (22)
Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells. (2019) (22)
E1A: Tumor suppressor or oncogene? Preclinical and clinical investigations ofE1A gene therapy (2001) (22)
Oxygen sensor boosts growth factor signaling (2009) (21)
The suppression of MAD1 by AKT‐mediated phosphorylation activates MAD1 target genes transcription (2009) (21)
EPOX Inhibits Angiogenesis by Degradation of Mcl-1 through ERK Inactivation (2009) (21)
Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase (2011) (21)
Differential amplification of the TGF-alpha gene in human gliomas. (1990) (21)
Author Correction: PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis (2020) (21)
KDM 2 A promotes lung tumorigenesis by epigenetically enhancing ERK 1 / 2 signaling (2013) (21)
E1A inhibition of radiation-induced NF-kappaB activity through suppression of IKK activity and IkappaB degradation, independent of Akt activation. (2001) (21)
Ferroptosis: a promising target for cancer immunotherapy. (2021) (20)
PRMT1 enhances oncogenic arginine methylation of NONO in colorectal cancer (2021) (20)
E1A Sensitizes Cancer Cells to TRAIL-Induced Apoptosis through Enhancement of Caspase Activation (2005) (20)
Sciellin mediates mesenchymal-to-epithelial transition in colorectal cancer hepatic metastasis (2016) (20)
Conformational stability of a snake cardiotoxin. (2009) (20)
Antitumor Agents. 282. 2'-(R)-O-acetylglaucarubinone, a quassinoid from Odyendyea gabonensis as a potential anti-breast and anti-ovarian cancer agent. (2010) (20)
MZF-1/Elk-1 interaction domain as therapeutic target for protein kinase Cα-based triple-negative breast cancer cells (2016) (20)
Sodium/Glucose Co-transporter 1 Expression Increases in Human Diseased Prostate (2012) (20)
Preparation and characterization of liposomal-lipophilic tumor necrosis factor. (1991) (19)
Growth inhibition of breast cancer cells by celecoxib (2001) (19)
Targeted endostatin-cytosine deaminase fusion gene therapy plus 5-fluorocytosine suppresses ovarian tumor growth (2013) (19)
Expression of PEA3 and Lack of Correlation Between PEA3 and HER-2/neu Expression in Breast Cancer (2006) (19)
Identification of a GαGβγ, AKT and PKCα signalome associated with invasive growth in two genetic models of human breast cancer cell epithelial-to-mesenchymal transition. (2012) (19)
Interferon‐inducible protein IFIXα inhibits cell invasion by upregulating the metastasis suppressor maspin (2008) (19)
Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8+ T Cells and Histone Acetyltransferases (2017) (19)
Transcriptional upregulation and activation of p55Cdc via p34cdc2 in Taxol-induced apoptosis (2001) (18)
Implication of nuclear EGFR in the development of resistance to anticancer therapies (2011) (18)
Activation of murine double minute 2 by Akt in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis. (2010) (18)
Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer. (1999) (18)
Endostatin-cytosine deaminase fusion protein suppresses tumor growth by targeting neovascular endothelial cells. (2006) (18)
De-acetylation and degradation of HSPA5 is critical for E1A metastasis suppression in breast cancer cells (2014) (18)
Phosphorylation of ARD1 by IKKbeta contributes to its destabilization and degradation. (2009) (18)
The adenoviral E1A induces p21WAF1/CIP1 expression in cancer cells. (2003) (17)
Cancer-Targeted BikDD Gene Therapy Elicits Protective Antitumor Immunity against Lung Cancer (2011) (17)
Lymphotoxin-β Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer (2017) (17)
Loss of Aurora A / STK 15 / BTAK Overexpression Correlates with Transition of in Situ to Invasive Ductal Carcinoma of the Breast (2003) (17)
Advances in Brief The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells (2004) (17)
TNF cytotoxicity: effects of HER-2/neu expression and inhibitors of ADP-ribosylation. (1994) (17)
E1A-Mediated Inhibition of HSPA5 Suppresses Cell Migration and Invasion in Triple-Negative Breast Cancer (2014) (17)
CHM-1 induces apoptosis via p38-mediated upregulation of DR5 expression in human ovarian cancer SKOV3 cells. (2011) (17)
The Anti-Tumor Activity of E1A and its Implications in Cancer Therapy (2014) (16)
Prostate‐specific antitumor activity by probasin promoter‐directed p202 expression (2003) (16)
Expression of metastasis suppressor BRMS1 in breast cancer cells results in a marked delay in cellular adhesion to matrix (2014) (16)
The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy (2017) (16)
Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression. (2018) (16)
Breast cancer chemosensitivity (2007) (16)
Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. (2019) (16)
Therapy-induced expression of NF-kappaB portends poor prognosis in patients with localized esophageal cancer undergoing preoperative chemoradiation. (2009) (16)
RGS2-mediated translational control mediates cancer cell dormancy and tumor relapse. (2021) (15)
Effects of truncation of human pro-tumor necrosis factor transmembrane domain on cellular targeting. (1993) (15)
Mutant Bik expression mediated by the enhanced minimal topoisomerase IIα promoter selectively suppressed breast tumors in an animal model (2006) (15)
TIE2 Associates with Caveolae and Regulates Caveolin-1 To Promote Their Nuclear Translocation (2017) (15)
Hippo coactivator YAP1 upregulates SOX9 and endows stem-like properties to esophageal cancer cells (2014) (15)
YY1 and HDAC9c transcriptionally regulate p38-mediated mesenchymal stem cell differentiation into osteoblasts. (2018) (15)
Carglumic acid promotes apoptosis and suppresses cancer cell proliferation in vitro and in vivo. (2015) (15)
Dicer Elicits Paclitaxel Chemosensitization and Suppresses Cancer Stemness in Breast Cancer by Repressing AXL. (2016) (14)
ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer (2021) (14)
Principles and treatment strategies for the use of Chinese herbal medicine in patients at different stages of coronavirus infection. (2020) (14)
The retinoblastoma gene product, Rb, represses neu expression through two regions within the neu regulatory sequence. (1994) (14)
Identification of a specific DNA region required for enhanced transcription of HER2/neu in the MDA-MB453 breast cancer cell line. (1996) (14)
NF-kB mediated transcriptional upregulation of Twist 1 Epithelial-mesenchyme transition induced by TNF-a requires (2012) (14)
In vitro synthesis of an N-myristoylated fusion protein that binds to the liposomal surface. (1996) (14)
HER-2/Neu signaling and therapeutic approaches in breast cancer. (2002) (14)
Erratum: P53 regulates epithelial, mesenchymal transition and stem cell properties through modulating miRNAs (Nature Cell Biology (2011) 13 (317-323)) (2011) (14)
PARP inhibitors as precision medicine for cancer treatment (2017) (13)
A novel CRM1‐dependent nuclear export signal in adenoviral E1A protein regulated by phosphorylation (2006) (13)
Greater enhancement of chemosensitivity by caffeine in high-p185neu-expressing human non-small-cell lung cancer cell lines. (1994) (13)
E 1 A-mediated Paclitaxel Sensitization in HER-2 / neu-overexpressing Ovarian Cancer SKOV 3 . ip 1 through Apoptosis Involving the Caspase-3 Pathway 1 (2000) (13)
The status of tyrosyl residues in a Formosan cobra cardiotoxin. (1978) (13)
Regulation of therapeutic resistance in cancers by receptor tyrosine kinases. (2016) (13)
JAK 2-binding long noncoding RNA promotes breast cancer brain metastasis (2019) (13)
Blood AST, ALT and UREA/BUN Level Analysis (2013) (13)
Activation of phagocytosis by immune checkpoint blockade (2018) (13)
MEASUREMENT of Protein 53 Diffusion Coefficient in Live HeLa Cells Using Raster Image Correlation Spectroscopy (RICS). (2010) (12)
High RPS3A expression correlates with low tumor immune cell infiltration and unfavorable prognosis in hepatocellular carcinoma patients. (2020) (12)
Proapoptotic and antitumor activities of adenovirus-mediated p202 gene transfer. (2002) (12)
Ceramide does not act as a general second messenger for ultraviolet-induced apoptosis (2002) (12)
Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma. (2020) (12)
A delayed chemically induced tumorigenesis in Brca2 mutant mice (2004) (12)
Ultraviolet irradiation induces BRCA2 protein depletion through a p53-independent and protein synthesis-dependent pathway. (2001) (12)
The effects of metformin on pathologic complete response (pCR) rates in diabetic breast cancer (BC) patients receiving neoadjuvant systemic therapy (NST) (2008) (12)
Molecular profile of advanced-stage transitional cell carcinoma of the ovary. (1997) (11)
POMC maintains tumor‐initiating properties of tumor tissue‐derived long‐term‐cultured breast cancer stem cells (2017) (11)
Intracaecal Orthotopic Colorectal Cancer Xenograft Mouse Model. (2017) (11)
Targeted BikDD Expression Kills Androgen-Dependent and Castration-Resistant Prostate Cancer Cells (2014) (11)
Nuclear Functions and Trafficking of Receptor Tyrosine Kinases (2013) (11)
CARMA 3 is Crucial for EGFR-Induced Activation of NFk B and Tumor Progression (2011) (11)
Functional roles of the human ribonuclease A superfamily in RNA metabolism and membrane receptor biology. (2019) (11)
Triplex formation at the rat neu oncogene promoter. (1994) (11)
Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells (2019) (11)
Rapid detection of two-protein interaction with a single fluorophore by using a microfluidic device. (2010) (11)
Abstract 5169: Flow-proteometric analysis of single signaling complex. (2013) (11)
ErbB 2-Mediated Src and Signal Transducer and Activator of Transcription 3 Activation Leads to Transcriptional Up-Regulation of p 21 Cip 1 and Chemoresistance in Breast Cancer Cells (2009) (11)
Inhibition of focal contact formation in cells transformed by p185neu (1999) (10)
H2O2 induces nuclear transport of the receptor tyrosine kinase c-MET in breast cancer cells via a membrane-bound retrograde trafficking mechanism (2019) (10)
Nuclear ErbB 2 Enhances Translation and Cell Growth by Activating Transcription of Ribosomal RNA Genes (2011) (10)
De-glycosylated membrane PD-L1 in tumor tissues as a biomarker for responsiveness to atezolizumab (Tecentriq) in advanced breast cancer patients. (2022) (10)
High speed digital protein interaction analysis using microfluidic single molecule detection system. (2010) (10)
BIK ubiquitination by the E3 ligase Cul5-ASB11 determines cell fate during cellular stress (2019) (10)
Targeting positive feedback between BASP1 and EGFR as a therapeutic strategy for lung cancer progression (2020) (10)
Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma. (2020) (10)
Suppressing HER2/neu-mediated cell transformation by transcriptional repressors. (2000) (10)
The potential role of YAP in Axl-mediated resistance to EGFR tyrosine kinase inhibitors. (2019) (10)
Enhanced MDM2 Oncoprotein Expression in Soft Tissue Sarcoma: Several Possible Regulatory Mechanisms (1997) (9)
PARG inhibition limits HCC progression and potentiates the efficacy of immune checkpoint therapy. (2022) (9)
Irradiation-induced dynamic changes of gene signatures reveal gain of metastatic ability in nasopharyngeal carcinoma. (2019) (9)
Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 main protease by tafenoquine in vitro (2020) (9)
Involvement of cdc2-mediated phosphorylation in the cell cycle-dependent regulation of p185neu (1997) (9)
JARID 1 D Is a Suppressor and PrognosticMarker of Prostate Cancer Invasion and Metastasis (2016) (9)
New Approaches on Cancer Immunotherapy. (2019) (9)
Scutellaria barbata D. Don Inhibits the Main Proteases (Mpro and TMPRSS2) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (2021) (9)
Nuclear receptor tyrosine kinase transport and functions in cancer. (2020) (9)
The effect of ephrin-A1 on resistance to Photofrin-mediated photodynamic therapy in esophageal squamous cell carcinoma cells (2015) (9)
Microfluidic three-dimensional hydrodynamic flow focusing for the rapid protein concentration analysis. (2012) (9)
Potential natural products that target the SARS-CoV-2 spike protein identified by structure-based virtual screening, isothermal titration calorimetry and lentivirus particles pseudotyped (Vpp) infection assay (2021) (9)
Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer (2022) (9)
The stabilization of PD-L1 by the endoplasmic reticulum stress protein GRP78 in triple-negative breast cancer. (2020) (9)
Targeting HER-2/neu-Overexpressing Cancer Cells with Transcriptional Repressor Genes Delivered by Cationic Liposome (1999) (9)
IκB Kinase Promotes Tumorigenesis through Inhibition of Forkhead FOXO3a (2007) (9)
Exogenous expression of human SGLT1 exhibits aggregations in sodium dodecyl sulfate polyacrylamide gel electrophoresis. (2013) (9)
A novel ligand-receptor relationship between families of ribonucleases and receptor tyrosine kinases (2018) (9)
The role of amino functions in recombinant human tumor necrosis factor in expression of biological activity. (1992) (9)
NONO phase separation enhances DNA damage repair by accelerating nuclear EGFR-induced DNA-PK activation. (2021) (8)
Role of cancer stem cells in brain tumors (2012) (8)
Emerging molecular targets in esophageal cancers. (2007) (8)
Cytoplasmic expression of p 21 CIP 1 / WAF 1 is correlated with IKKß overexpression in human breast cancers (8)
Musashi-1 promotes stress-induced tumor progression through recruitment of AGO2 (2020) (8)
Collagen-homology domain 1 deletion mutant of Shc suppresses transformation mediated by neu through a MAPK-independent pathway (1999) (8)
Inhibition of CDK2 reduces EZH2 phosphorylation and reactivates ERα expression in high-grade serous ovarian carcinoma. (2020) (8)
E1A Cancer Gene Therapy (2002) (8)
Material for Akt-Mediated Phosphorylation of EZH 2 Suppresses Methylation of Lysine 27 in Histone H 3 (2005) (8)
Rational combination of immunotherapy for triple negative breast cancer treatment. (2017) (8)
Imatinib (STI571) Inhibits the Expression of Angiotensin-Converting Enzyme 2 and Cell Entry of the SARS-CoV-2-Derived Pseudotyped Viral Particles (2021) (7)
RASAL2: wrestling in the combat of Ras activation. (2013) (7)
Phosphorylation and stabilization of PD-L1 by CK2 suppresses dendritic cell function. (2022) (7)
Establishment of a human embryonic stem cell line with homozygous TP53 R248W mutant by TALEN mediated gene editing (2018) (7)
Localizing the EGF receptor - Reply (2002) (7)
Development and characterization of anti-galectin-9 antibodies that protect T cells from galectin-9-induced cell death (2022) (7)
Proteasome inhibition enhances the killing effect of BikDD gene therapy. (2015) (7)
A homozygous p53 R282W mutant human embryonic stem cell line generated using TALEN-mediated precise gene editing. (2018) (7)
Cancer Gene Therapy by Viral and Non-viral Vectors (2014) (7)
Receptor Tyrosine Kinases in the Nucleus: Nuclear Functions and Therapeutic Implications in Cancers (2014) (7)
Delivery of DNA to tumor cells using cationic liposomes. (2004) (6)
PKCδ-mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs (2021) (6)
Cigarette smoke-induced LKB1/AMPK pathway deficiency reduces EGFR TKI sensitivity in NSCLC (2020) (6)
Expression and Clinical Significance of Protein Kinase RNA–Like Endoplasmic Reticulum Kinase and Phosphorylated Eukaryotic Initiation Factor 2&agr; in Pancreatic Ductal Adenocarcinoma (2019) (6)
mMAPS: A Flow-Proteometric Technique to Analyze Protein-Protein Interactions in Individual Signaling Complexes (2014) (6)
MRNIP condensates promote DNA double-strand break sensing and end resection (2022) (6)
Tyrosine Kinase Inhibitor Emodin Suppresses Growth of HER-2 / neu-overexpressing Breast Cancer Cells in Athymic Mice and Sensitizes These Cells to the Inhibitory Effect of Paclitaxel 1 (1999) (6)
Natural tannins as anti-SARS-CoV-2 compounds (2022) (6)
A chirality‐dependent action of vitamin C in suppressing Kirsten rat sarcoma mutant tumor growth by the oxidative combination: Rationale for cancer therapeutics (2020) (6)
Nuclear Functions of Receptor Tyrosine Kinases (2015) (5)
Targeted expression of BikDD combined with metronomic doxorubicin induces synergistic antitumor effect through Bax activation in hepatocellular carcinoma (2015) (5)
Differential activity of the RVF enhancer element in the decreased expression of the neu oncogene in NR‐6 cells versus parental Swiss Webster 3T3 cells (1993) (5)
Powering Tumor Metastasis with Recycled Fuel. (2016) (5)
Screening strategy of TMPRSS2 inhibitors by FRET-based enzymatic activity for TMPRSS2-based cancer and COVID-19 treatment. (2021) (5)
V-abl confers resistance and growth advantage to TNF-α in NIH3T3 cells (1990) (5)
Transition and Epithelial Cell Invasion Krüppel-Like Factor 8 Induces Epithelial to Mesenchymal (2007) (5)
An essential role of PRMT1-mediated EGFR methylation in EGFR activation by ribonuclease 5. (2019) (5)
A flow-proteometric platform for analyzing protein concentration (FAP): Proof of concept for quantification of PD-L1 protein in cells and tissues. (2018) (5)
Renaturation of a reduced Taiwan cobra cardiotoxin. (1978) (5)
Pneumatically Actuated Soft Micromold Device for Fabricating Collagen and Matrigel Microparticles. (2017) (5)
Correlation of Snail expression and survival in patients with early-stage triple-negative breast cancer (TNBC). (2010) (5)
A tumor vessel-targeting fusion protein elicits a chemotherapeutic bystander effect in pancreatic ductal adenocarcinoma. (2017) (5)
Novel Signaling Pathways in Breast Cancer (2006) (5)
Transcriptional regulation of neu by RB and E1A in rat-1 cells. (1994) (5)
Glycosylation of Siglec15 promotes immunoescape and tumor growth. (2021) (5)
Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells. (2021) (5)
Racial profiling harms science (2019) (5)
Molecular cloning and characterization of v-mos-activated transformation-associated proteins. (1992) (5)
Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth (2018) (4)
S 6 K 1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer (2014) (4)
Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis (2022) (4)
Selective expression of constitutively active pro-apoptotic protein BikDD gene in primary mammary tumors inhibits tumor growth and reduces tumor initiating cells. (2015) (4)
Corrigendum: Blocking c-Met–mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors (2016) (4)
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer (2016) (4)
Endothelial p130cas confers resistance to anti-angiogenesis therapy (2020) (4)
Rodent p53 suppresses the transforming activity of the activated Neu oncogene by modulating the Basal promoter activity of Neu. (1995) (4)
Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation (2021) (4)
Deglycosylation of PD-L 1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer (2018) (4)
Definition of PKC-α , CDK 6 , and MET as therapeutic targets in triple-negative breast cancer (2014) (4)
Regulation of Breast Cancer Metastasis by Atypical Chemokine Receptors (2009) (4)
GTPBP4 promotes hepatocellular carcinoma progression and metastasis via the PKM2 dependent glucose metabolism (2022) (4)
Hereditary retinoblastoma iPSC model reveals aberrant spliceosome function driving bone malignancies (2022) (4)
A novel alteration in the epidermal growth factor receptor gene is frequently detected in human non-small cell lung cancer (1990) (4)
Advances in Brief A New Role of Protein Phosphatase 2 A in Adenoviral E 1 A Protein-Mediated Sensitization to Anticancer Drug-Induced Apoptosis in Human Breast Cancer Cells (2004) (4)
AMBRA1 Promotes TGFβ Signaling via Nonproteolytic Polyubiquitylation of Smad4 (2021) (4)
Downstream signal transduction defects that suppress transformation in two revertant cell lines expressing activated rat neu oncogene. (1993) (4)
Preclinical Development Targeting the IKK b / mTOR / VEGF Signaling Pathway as a Potential Therapeutic Strategy for Obesity-Related Breast Cancer (2012) (4)
Suppresses Tumor Growth in Mice Cells Induces Apoptosis via the mTOR / STAT 3 Pathway and Targeting YB-1 in HER-2 Overexpressing Breast Cancer (2008) (4)
Prospects of Coffee Leaf against SARS-CoV-2 Infection (2022) (4)
Evading immune surveillance via tyrosine phosphorylation of nuclear PCNA. (2021) (4)
Author Correction: CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer (2020) (3)
Differential expression of the neu oncogene in mouse liver and pancreatic cell lines. (1992) (3)
Suppression of breast cancer cells resistant to a pure anti-estrogen with CAR-transduced natural killer cells. (2021) (3)
Disulfiram blocked cell entry of SARS-CoV-2 via inhibiting the interaction of spike protein and ACE2. (2022) (3)
Development of automated high throughput single molecular microfluidic detection platform for signal transduction analysis (2016) (3)
The VEGF-C/Flt-4 Axis Promotes Invasion and Metastasis of Cancer Cells (DOI:10.1016/j.ccr.2006.02.018) (2007) (3)
P27kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells (Cancer Research (June 1, 2004) 64 (3981-3986)) (2008) (3)
Functional significance of gain-of-function H19 lncRNA in skeletal muscle differentiation and anti-obesity effects (2021) (3)
TIE 2-mediated tyrosine phosphorylation of H 4 regulates DNA damage response by recruiting ABL 1 (2016) (3)
HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF- k B Pathway* (2000) (3)
Tumor and Stem Cell Biology Cytokine Receptor CXCR 4 Mediates Estrogen-Independent Tumorigenesis , Metastasis , and Resistance to Endocrine Therapy in Human Breast Cancer (2011) (3)
Advances in Liposome-Based Targeted Gene Therapy of Cancer (2012) (3)
Targeting 2-oxoglutarate dehydrogenase for cancer treatment. (2022) (3)
Characterization and Modeling of Monocyte/Macrophage Presentation of Membrane TNF (1992) (3)
PP2A Deficiency Enhances Carcinogenesis of Lgr5+ Intestinal Stem Cells Both in Organoids and In Vivo (2019) (3)
Abstract 989: The crosstalk of mTOR/S6K1 and Hedgehog pathways (2012) (3)
Single oral dose acute and subacute toxicity of a c-MET tyrosine kinase inhibitor and CDK 4/6 inhibitor combination drug therapy. (2018) (2)
Tafenoquine and its derivatives as inhibitors for the severe acute respiratory syndrome coronavirus 2 (2022) (2)
From polyploidy to polyploidy reversal: its role in normal and disease states. (2022) (2)
Advances in Brief Inhibition of Angiogenesis and Induction of Apoptosis Are Involved in E 1 A-mediated Bystander Effect and Tumor Suppression 1 (2000) (2)
TNF a induces HIF-1 a expression through activation of IKK b (2009) (2)
E1A-Mediated Gene Therapy. (2001) (2)
Abstract LB-202: 14-3-3ζ turns TGF-β's function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2 (2015) (2)
Mechanisms of Action and Resistance of Trastuzumab in Breast Cancer (2018) (2)
Generation of an induced pluripotent stem cell line from an individual with a heterozygous RECQL4 mutation (2018) (2)
Targeting the ALK–CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex (2022) (2)
Erratum: Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer (Cancer Research (January 1, 2005) 65 (338-348)) (2005) (2)
Advances in Brief Akt Activation by Estrogen in Estrogen Receptor-negative Breast Cancer Cells (2001) (2)
Efficient systemic DNA delivery to the tumor by self-assembled nanoparticle (2013) (2)
The launch of the american journal of translational research. (2009) (2)
Erratum to: E1A-Mediated Inhibition of HSPA5 Suppresses Cell Migration and Invasion in Triple-Negative Breast Cancer (2017) (2)
Arginine methylation of EGFR: a new biomarker for predicting resistance to anti-EGFR treatment. (2017) (2)
Abstract 4710: p53 regulates epithelial-mesenchymal transition (EMT) and stem cell properties through modulation of miRNAs (2011) (2)
Erratum: Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers (Science Translational Medicine DOI: 10.1126/scitranslmed.aao4307) (2019) (2)
Regulation of SETD2, a histone methyltransferase, in advanced clear cell renal cell carcinoma (ccRCC). (2012) (2)
Effects of estrogen receptor expression on growth and transformation of cells overexpressing neu. (1996) (2)
Discussion: Molecular Therapeutics and Pharmacogenomics (2003) (2)
High-resolution pro fi ling of histone h 3 lysine 36 trimethylation in metastatic renal cell carcinoma (2015) (2)
149 INVITED Are there rational novel targets for pancreatic cancer therapeutics? Observations from the M.D. Anderson Cancer Center SPORE in Pancreatic Cancer (2007) (2)
Peimine inhibits variants of SARS‐CoV‐2 cell entry via blocking the interaction between viral spike protein and ACE2 (2022) (2)
Biochemical fractionation of membrane receptors in the nucleus. (2015) (2)
Safety and efficacy of quadrapeutics versus chemoradiation in head and neck carcinoma xenograft model. (2015) (2)
The N-linked glycosylations of TIGIT Asn32 and Asn101 facilitate PVR/TIGIT interaction. (2021) (2)
Nanofluidic devices for single molecule identification (2008) (2)
Abstract 13: PRMT1 as a therapeutic target in diffuse large B-cell lymphoma (2017) (2)
Analysis of Individual Signaling Complexes by mMAPS, a Flow‐Proteometric System (2016) (2)
A feed forward mechanism for adenoviral E1A protein-mediated sensitization to apoptosis (2005) (1)
EZH2/hSULF1 axis mediates receptor tyrosine kinase signaling to shape cartilage tumor progression (2022) (1)
Digital Receptor Occupancy Assay in Quantifying On- and Off-Target Binding Affinities of Therapeutic Antibodies. (2020) (1)
Sa1851 Prognostic Significance of TGF-β Signaling in Human Hepatocellular Carcinoma (2015) (1)
Fabrication of silica nanochannels via scanned coaxial electrospinning (2005) (1)
Targeting Y-box binding protein-1 (YB-1) in Her-2 over-expressing breast cancer cells induces apoptosis via the signal transducer and activator or transcription-3 (STAT3) pathway and suppresses tumor growth. (2008) (1)
Downregulation of CXCR4 by E1A (2005) (1)
Advances in Brief Ultraviolet Irradiation Induces BRCA 2 Protein Depletion through a p 53-independent and Protein Synthesis-dependent Pathway 1 (2001) (1)
Abstract 3: Targeting epigenetic modifiers in diffuse large B-cell lymphoma (2017) (1)
Tumor and Stem Cell Biology Hippo Coactivator YAP 1 Upregulates SOX 9 and Endows Esophageal Cancer Cells with Stem-like Properties (2014) (1)
Post-EMT: Cadherin-11 mediates cancer hijacking fibroblasts (2019) (1)
Metabolic remodeling in tumor-associated macrophages contributing to antitumor activity of cryptotanshinone by regulating TRAF6-ASK1 axis (2022) (1)
14-3-3 z Cooperates with ErbB2 to Promote Ductal Carcinoma In Situ Progression to Invasive Breast Cancer by Inducing Epithelial-Mesenchymal Transition (2009) (1)
Snail induces dormancy in disseminated luminal type A breast cancer through Src inhibition. (2022) (1)
Prostate Cancer Cell Growth Emodin Down-Regulates Androgen Receptor and Inhibits (2005) (1)
Dysregulation of MicroRNAs in cancer (2012) (1)
Exploiting induced vulnerability to overcome PARPi resistance and clonal heterogeneity in BRCA mutant triple-negative inflammatory breast cancer. (2022) (1)
On mammary gland growth factors: roles in normal development and in cancer. (2012) (1)
CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line? (2018) (1)
PD-L1 deficiency sensitizes tumor cells to DNA-PK inhibition and enhances cGAS-STING activation. (2022) (1)
Multi-organ metastasis as destination for breast cancer cells guided by biomechanical architecture. (2021) (1)
Transcriptional repression of the neu protooncogene by the adenovirus 5 ElA gene products ( gene regulation / c-erbB2 / HER-2 ) (1)
Tumor-associated nonmyelinating Schwann cell–expressed PVT1 promotes pancreatic cancer kynurenine pathway and tumor immune exclusion (2023) (1)
ASPH-notch Axis guided Exosomal delivery of Prometastatic Secretome renders breast Cancer multi-organ metastasis (2019) (1)
14-3-3 z Cooperates with ErbB 2 to Promote Ductal Carcinoma In Situ Progression to Invasive Breast Cancer by Inducing Epithelial-Mesenchymal Transition (2009) (1)
Correction: Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer (2019) (1)
Correction: De-acetylation and degradation of HSPA5 is critical for E1A metastasis suppression in breast cancer cells [Oncotarget. 5, 21, (2014) (10558-70)] doi: 10.18632/oncotarget.2510. (2016) (1)
Short Communication Loss of Aurora A/STK15/BTAK Overexpression Correlates with Transition of in Situ to Invasive Ductal Carcinoma of the Breast (2003) (1)
MITR IS A SWITH THAT PROMOTES OSTEOGENESIS AND INHIBITS ADIPOGENESIS OF MESENCHYMAL STEM CELLS BY INACTIVATING PPAR γ -2 is a (2011) (1)
Abstract 4018: Mutations of HER2 at L755 residue results in HER2 nuclear accumulation and enhances breast cancer stem cell activity (2018) (1)
Erratum: Suspension survival mediated by PP2A-STAT3-Col XVII determines tumour initiation and metastasis in cancer stem cells (2016) (1)
Beyond NF-κB activation: nuclear functions of IκB kinase α (2013) (1)
Abstract 5682: Synergism of PARP inhibitor and MET inhibitor in multiple cancer types with intrinsic and acquired PARP inhibitor resistances (2020) (1)
An optimized protocol for PD-L1 pathological assessment with patient sample deglycosylation to improve correlation with therapeutic response (2022) (1)
14-3-3 Z Overexpression Defines High Risk for Breast Cancer Recurrence and Promotes Cancer Cell Survival (2009) (1)
V-abl confers resistance and growth advantage to TNF-alpha in NIH3T3 cells. (1990) (1)
EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer (2014) (1)
Endothelial p130cas confers resistance to anti-angiogenesis therapy (2022) (1)
Endoscopic ultrasound-guided fine-needle biopsy as a tool for studying the intra-tumoral microbiome in pancreatic ductal adenocarcinoma: a pilot study (2022) (1)
Prospects of the potential strategies to improve the efficacy of anti‐PD‐1/PD‐L1 therapy (2022) (1)
Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates. (2022) (1)
Hyperthermia enhances the cytotoxicity of National Institutes of Health 3T3 cells transfected with a noncleavable transmembrane pro-tumor necrosis factor deletion mutant. (1994) (1)
Asian Scientists and the "Glass Ceiling" (2005) (1)
Abstract A16: Metformin is a potential nontoxic adjuvant to enhance the efficacy of non-PDL1/PD-1 targeting immune therapies (2020) (0)
Cancer Gene Therapy by Tissue-specific and Cancer-targeting Promoters (2014) (0)
Abstract 1962: TGF-β/SMAD2 signaling drives tumor-progression via c-KIT/STAT3-signaling in advanced HCC (2015) (0)
The Anti-Tumor Activity of E1A and its Implications in Cancer Therapy (2014) (0)
Original Article S6K1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer (2014) (0)
Abstract 976: Hypoxic microenvironment promotes breast cancer stem cells through regulation of Polycomb protein expression (2011) (0)
AD Award Number : DAMD 17-001-0312 TITLE : p 202 as a Potential Therapeutic Gene for Breast Cancer (0)
641 TGF-β? Regulated E3 Ligase Are Novel Therapeutic Targets for Primary Liver Cancer (2014) (0)
Abstract 721: Putative molecular mechanism contributing AZD6244 resistance in lung cancer (2011) (0)
Raster Image Correlation Spectroscopy for Anti-Cancer Drug Screening Based on the Identification of Molecular Dynamics (2010) (0)
Erratum: Upregulation of IKKα/IKKβ by integrin-linked kinase is required for HER2/neu-induced NF-κB antiapoptotic pathway (Oncogene (2004) 23 (3883-3887) DOI:10.1038/sj.onc.1207485) (2004) (0)
Training Program in Breast Cancer Research at the University of Texas M.D. Anderson Cancer Center (2004) (0)
Development of Therapeutic Genes for Breast Cancer Treatment (2007) (0)
Molecular Mechanisms of snoRNA-IL-15 Crosstalk in Adipocyte Lipolysis and NK Cell Rejuvenation (2022) (0)
Abstract 4051: EGF receptor trafficking from the cell surface to the nucleus through the Golgi, ER, and nuclear envelope (2011) (0)
594 Dielectrophoresis (DEP) as sorting technology for microdiagnosis in breast cancer (2004) (0)
The tumor suppressor activity of an adenovirous E1A mutant protein in human breast cancer (2006) (0)
Photofrin photosensitizer inhibits the expression of EGFR independent of light irradiation in cancer cells (2011) (0)
Abstract 3465: The effect of ephrin-A1 on the resistance of photodynamic therapy in esophageal cancer cells (2012) (0)
Breast cancer gene therapy (2006) (0)
The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy (2017) (0)
Abstract A57: The novel function of nuclear ErbB-2 in regulating transcription of rRNA genes (2011) (0)
Consensus tracking in sensor networks with periodic sensing and switching connected topologies (2015) (0)
When all the colonies are blue (2005) (0)
Abstract B090: Tyrosine 211 phosphorylation of PCNA: A new paradigm of linking cell proliferation to cancer stemness and metastasis (2019) (0)
Advances in Brief Systemic Tumor Suppression by the Proapoptotic Gene bik 1 (2001) (0)
Editorial Board 2009: American Journal of Translational Research (ISSN 1943-8141) www.ajtr.orgPublisher: e-Century Publishing Corporation (www.e-Century.org). (2009) (0)
Abstract B40: The phosphorylation by activated-AMPK induces ERAD of PD-L1 through abnormal glycosylation (2020) (0)
Abstract 3028: Reactive oxygen species induced nuclear translocation of c-MET via INTERNET mechanism (2017) (0)
14-3-3ζ Cooperates with ErbB2 to Promote Progression of Ductal Carcinoma in Situ to Invasive Breast Cancer by Inducing Epithelial-Mesenchymal Transition (2009) (0)
Editorial Board 2010 American Journal of Translational Research (ISSN 1943-8141): www.ajtr.org Publisher: e-Century Publishing Corporation (www.e-Century.org). (2010) (0)
Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor family (2012) (0)
Editorial Board 2010 (2010) (0)
elerates Mammary Tumorigenesis (2010) (0)
Abstract LB-131: Targeting expression of EZH2 with increased H3K27 trimethylation activity drives and synergizes with oncogene to promote mammary tumorigenesis in genetically engineered mouse models (2017) (0)
Localizing the EGF receptor (multiple letters) [1] (2002) (0)
P70-S Despite Rumors to the Contrary, PCNA Really IS Phosphorylated (2007) (0)
Activation of Aurora A kinase increases YAP stability via blockage of autophagy (2019) (0)
1002. L1 Cell Adhesion Molecule, a Novel Target of Prostate Cancer Gene Therapy (2006) (0)
Author Correction: A hypoxia-responsive TRAF6–ATM–H2AX signalling axis promotes HIF1α activation, tumorigenesis and metastasis (2020) (0)
Abstract 5129: Model osteosarcoma by Li-Fraumeni syndrome patient-specific induced pluripotent stem cells (2015) (0)
Advances in Brief Tumor Suppression and Sensitization to Tumor Necrosis Factor a-induced Apoptosis by an Interferon-inducible Protein , p 202 , in Breast Cancer Cells 1 (2000) (0)
Short Communication Neutralizing Antibodies against Epidermal Growth Factor and ErbB-2lneu Receptor Tyrosine Kinases Down-Regulate Vascular Endothelial Growth Factor Production by Tumor Cells in Vitro and in Vivo Angiogenic Implications for Signal Transduction Solid Tumors Therapy of (2007) (0)
Abstract 3290: A novel model of breast cancer metastasis: Killing two birds with one stone (2012) (0)
Endoscopic ultrasound-guided fine-needle biopsy as a tool for studying the intra-tumoral microbiome in pancreatic ductal adenocarcinoma: a pilot study (2022) (0)
Role of tryptophanyl and tyrosyl residues in maintaining the active conformation of α-bungarotoxin (1981) (0)
Advances in Brief HER-2 / neu Promotes Androgen-independent Survival and Growth of Prostate Cancer Cells through the Akt Pathway 1 (2000) (0)
Evaluation of 89Zr-Labeled Anti-PD-L1 Monoclonal Antibodies Using DFO and Novel HOPO Analogues as Chelating Agents for Immuno-PET (2023) (0)
Functional significance of gain-of-function H19 lncRNA in skeletal muscle differentiation and anti-obesity effects (2021) (0)
Large Molecule Therapeutics Targeted BikDD Expression Kills Androgen-Dependent and Castration-Resistant Prostate Cancer Cells (2014) (0)
The regulation of tissue-specific casein gene expression in transgenic animals (1989) (0)
Highly Mimetic Ex Vivo Lung-Cancer Spheroid-Based Physiological Model for Clinical Precision Therapeutics. (2023) (0)
RTRB-10TYROSINE KINASE RECEPTOR TIE2 REGULATES DNA REPAIR THROUGH THE PROTO-ONCOGENE ABL1 IN BRAIN TUMOR STEM CELLS (2015) (0)
Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. (2007) (0)
Molecular therapeutics and pharmacogenomics (2003) (0)
Cancer Therapy: Preclinical Caspase-Independent Cell Death Is Involved in the Negative Effect of EGF Receptor Inhibitors on Cisplatin in Non–Small Cell Lung Cancer Cells (2013) (0)
Methods and compositions for suppression of cell transformation by new (1991) (0)
Abstract 3298: ABL1 is required for Tie2-mediated DNA repair in brain tumor stem cells (2015) (0)
Nuclear Localization of Receptor Tyrosine Kinases in Cancers (2013) (0)
Dasatinib Increases MHCII Surface Levels and Can Synergize with Anti-PD1 Therapy to Increase the Anti-Tumor Effect in a Pre-Clinical Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Model (2020) (0)
Insulin-like growth factor-1 (IGF-1) receptor-induced resistance to trastuzumab (Herceptin) in breast cancer (BC) xenografts in athymic mice can be measured using 111In-IGF-1-E3R (2007) (0)
Editorial Board 2009 (2009) (0)
Generation of TetOff-inducible Ago2 stable clones for studying miRNA processing in vivo (2013) (0)
Abstract 3896: The Hippo coactivator YAP1 upregulates SOX9 and endows cancer stem cell properties in non-transformed cells and esophageal cancer cells (2014) (0)
STK15/BTAK/aurora-A expression in ductal carcinoma in situ of the breast (2001) (0)
Abstract P5-05-10: EIA-Induced PP2A Expression Prevents β-Trcp Mediated FOXO3a Degradation and Enhances Chemosensitization by Inhibiting TAK1/IKK Signaling (2010) (0)
The natural tannins oligomeric proanthocyanidins and punicalagin are potent inhibitors of infection by SARS-CoV-2 in vitro (2023) (0)
Galectin-9 blockade synergizes with ATM inhibition to induce potent anti-tumor immunity (2023) (0)
A novel ligand-receptor relationship between families of ribonucleases and receptor tyrosine kinases (2018) (0)
Abstract A49: S6K1 promotes invasiveness of breast cancer cells in a novel model of triple-negative breast cancer metastasis (2014) (0)
BRMS1 Suppresses Breast Cancer Metastasis to Bone via Its Regulation of MicroRNA-125b and Downstream Attenuation of TNF-alpha and HER2 Signaling Pathways (2013) (0)
Erratum: Systemic tumor suppression by the proapoptotic gene bik (Cancer Research (January 1, 2002) (8-12)) (2002) (0)
Optofluidic single molecule flow proteometry (2009) (0)
Abstract 3900: Genomic landscape of human cancer reveals dysregulated TGF-β signaling with prognostic significance (2015) (0)
Abstract 263: p38 MAPK is required for EGFR nuclear translocation (2010) (0)
Abstract 3911: A positive feedback loop between TGF-β and SCF mediates TGF-β1 ligand overexpression in advanced hepatocellular carcinoma (2015) (0)
Endoscopic Ultrasound-Guided Fine-Needle Biopsy As A Valuable Tool for Studying The Intra-Tumoral Microbiome in Pancreatic Ductal Adenocarcinoma (2021) (0)
Arginine methylation of EGFR in circulating tumor cells: A new biomarker for predicting resistance to anti-EGFR agents. (2017) (0)
Comprar Breast Cancer Chemosensitivity | Yu, Dihua | 9780387740379 | Springer (2008) (0)
Adenovirus Type 5 ElA Gene Products Act as Transformation (2004) (0)
Abstract 845: c-MET nuclear transportation via membrane-bounded retrograde trafficking in breast cancer cells (2019) (0)
Differential Regulation Of Tumor Suppressor PDCD4 Expression By Rapamycin (2011) (0)
Abstract B47: Stabilization of programmed death ligand-1 by epidermal growth factor enhances cancer cell immune escape (2017) (0)
Anti-tumor effect of Bik mutant (2004) (0)
Breast Cancer Cells Akt Activation by Estrogen in Estrogen Receptor-negative Updated Version (2001) (0)
Regulation of SETD2, a histone methyltransferase, in advanced clear cell renal cell carcinoma (ccRCC). (2012) (0)
Palmitoylation stabilizes PD-L1 to promote breast tumor growth (2018) (0)
Abstract #5672: The role of IKK\#946;/TSC1 regulation in tumorigenesis and insulin resistance (2009) (0)
Abstract 3205: Histone tyrosine phosphorylation determines glioblastoma cell survival (2018) (0)
stem-like properties to esophageal cancer cells Hippo coactivator YAP 1 upregulates SOX 9 and endows (2014) (0)
Transcriptional repression in cancer gene therapy: targeting HER-2/neu overexpression as an example (1999) (0)
Combination treatment of arsenic trioxide and osimertinib in recurrent and metastatic head and neck squamous cell carcinoma. (2022) (0)
Upregulation of IKKα/IKKβ by integrin-linked kinase is required for HER2/neu-induced NF-κB antiapoptotic pathway (2004) (0)
Abstract C171: Novel therapeutic strategies targeting the hedgehog signaling pathway and mTOR pathway in biliary tract cancer (BTC). (2013) (0)
Suppression Adenovirus E 1 A Mediate Two Distinct Mechanisms of Tumor-Terminal and Conserved Region 2 Domains of 2 The NH Updated (2002) (0)
Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression (2019) (0)
Abstract 5180: Nuclear receptor tyrosine kinase c-MET restrains efficacy of PARP inhibitor in pancreatic cancer cells (2020) (0)
PTEN Key to Herceptin Response in Her2-Positive Breast Cancer (2004) (0)
Original Article Exogenous expression of human SGLT1 exhibits aggregations in sodium dodecyl sulfate polyacrylamide gel electrophoresis (2013) (0)
Assessing metastatic potential of breast cancer cells based on EGFR dynamics (2019) (0)
ZRANB1 is an NBS1 deubiquitinase and a potential target to overcome radioresistance and PARP inhibitor resistance in triple-negative breast cancer (2022) (0)
177: ADAM9 coordinates genes in anoikis resistance for lung cancer metastases (2014) (0)
Abstract 6527: Targeting glycosylated PD-1 induces potent anti-tumor immunity (2020) (0)
Normal Cancer Normal Cancer Normal Cancer Normal Cancer Normal Cancer Patient 1 Patient 2 Patient 3 Patient 4 Patient (2016) (0)
Disruption of SLFN11 deficiency-induced CCL2 signaling and macrophage M2 polarization potentiates anti-PD-1 therapy efficacy in hepatocellular carcinoma. (2023) (0)
Abstract 2046: TGF-β drives tumor-progression via JAK/STAT3-signaling in advanced HCC. (2013) (0)
Crystal structure of the human FOXO3a-DBD bound to DNA (2008) (0)
Erratum: The stabilization of PD-L1 by the endoplasmic reticulum stress protein GRP78 in triple-negative breast cancer. (2020) (0)
Abstract 4074: Reversing acquired PARPi resistance of TNBC through combined inhibition of cMet and EGFR (2020) (0)
Regulation of Neu Oucogene Transcription by the Tax Gene Product of HTLV-I Involves both Positive and Negative Cis - Acting Elements (1992) (0)
Abstract 1496: Epithelial to mesenchymal transition and rapamycin sensitivity in cancer cell lines. (2013) (0)
418 Cytoplasmic localization of p21 cip1/WAF1 is a poor prognostic marker in the breast cancer patients (2004) (0)
Abstract 4017: Identifying Protein-Protein Interactions in Single Protein Complex level by Microchannel Device (2010) (0)
Original Article Carglumic acid promotes apoptosis and suppresses cancer cell proliferation in vitro and in vivo (2015) (0)
Repression of neu-induced clonogenicity by dimethylsulfoxide correlates with decreased levels of neu-encoded cell-surface p185 and changes in phosphotyrosine content of endogenous proteins. (1993) (0)
A CENTRAL ROLE OF INTERFERON SIGNALING IN ICB RESISTANCE (2017) (0)
Osteoprogenitor-GMP crosstalk underpins solid tumor-induced systemic immunosuppression and persists after tumor removal. (2023) (0)
Tumor and Stem Cell Biology FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization (2011) (0)
Trials and Tribulations in Developing Clinical Trials of Gene Therapy (2007) (0)
Author Correction: A hypoxia-responsive TRAF6–ATM–H2AX signalling axis promotes HIF1α activation, tumorigenesis and metastasis (2020) (0)
“VISA” Nanoparticles to Breast Cancer. (2009) (0)
Nanofluidic Strategies for Cancer Research (2016) (0)
Novel nuclear interaction of EGFR and STAT3 in the activation of iNOS/NO pathway (2004) (0)
Molecular characterization of SETD2, a histone methyltransferase, in clear cell renal cell carcinoma (ccRCC). (2012) (0)
Abstract 1792: FGFR3 mediated PARP1 tyrosine 158 phosphorylation promotes PARP inhibitor resistance (2022) (0)
Finding the bEST routes to cancer (2004) (0)
Multiple Genetic Alterations in Breast Cancer (1995) (0)
Nuclear transport of EGFR is through the integral trafficking from the endoplasmic reticulum to the nuclear envelope (2008) (0)
Abstract 1438: Breast cancer metastasis suppressor 1 (BRMS1) suppresses attachment and spreading of breast cancer cells on 2D and 3D extracellular matrix components by altering focal adhesion-associated signaling (2011) (0)
Effect of Epithelial-Mesenchymal Transition on EGFR Dynamics Revealed by Single-Particle Tracking (2018) (0)
Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors (2022) (0)
Abstract B17: Exosomal PD-L1 harbors active defense function to suppress T-cell activity and promote breast cancer tumor growth (2020) (0)
Abstract 1035: SETD2, a histone methyltransferase, is misregulated in advanced clear cell renal cell carcinoma (ccRCC) (2012) (0)
Abstract 5351: Phosphorylation of EZH2 at Thr487 is a marker for good prognosis in pancreatic cancer patients. (2013) (0)
Abstract 499: EGFR expression correlates with response to photodynamic therapy in esophageal cancer cells (2010) (0)
Pancreatic cancer targeted C-VISA-BikDD: DNA-liposome complex results in minimal toxicity in vivo. (2007) (0)
82. Targeted Pancreatic Cancer-Specific Gene Therapy Controlled by a Molecular-Engineered Human Cholecystokinin Type-A Receptor (CCKAR) Promoter in In Vivo Imaging Models (2005) (0)
Abstract 2895: Phosphorylation of EZH2 at T416 by CDK2 promotes development of mammary tumors with basal-like phenotype (2015) (0)
Cancer Therapy : Preclinical Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer (2009) (0)
Abstract 642: Vimentin is a novel anticancer therapeutic target (2010) (0)
Structure of the FOXO3a-DBD/DNA complex suggests the effects of post-translational modification (2008) (0)
EGFR^SGLT1InteractionDoesNotRespondtoEGFR Modulators,But Inhibition of SGLT1Sensitizes Prostate CancerCellstoEGFRTyrosineKinase Inhibitors (2013) (0)
Abstract LB-002: Methylation of the EGF receptor regulates signaling and therapeutic response (2016) (0)
Targeting and anti-cancer effect of Endostatin-cytosine deaminase fusion protein (2008) (0)
A Novel mRNA Signature Related to Immunity to Predict Survival and Immunotherapy Response in Hepatocellular Carcinoma (2022) (0)
Abstract C070: Investigation of the roles of BDKRB1 in pancreatic cancer progression and tumor microenvironment modulation (2022) (0)
Sphingosine kinase 1 promotes tumor immune evasion by regulating the MTA3-PD-L1 axis (2022) (0)
Cancer: Current concepts (1999) (0)
Abstract 3036: Interaction of proliferation cell nuclear antigen (PCNA) with c-Abl in cell proliferation and response to DNA damages in breast cancer (2012) (0)
Systemic gene therapy of HER-2/neu overexpressing breast cancer using radiation sensitizer E1A (2000) (0)
Independent control elements that expression in alternative Drosophil (germ-line transformation/sex-, stage-, and tissue-specific gene expri (2016) (0)
Abstract IA23: Marker-guided targeted therapy, PARP inhibitors, and novel post-translational modification of PD-L1 (2020) (0)
Deglycosylation of SLAMF7 in breast cancers enhances phagocytosis. (2022) (0)
Novel Signaling Pathway in Barrett's Esophagus and Development of Gene Therapy for Pancreatic Cancer (2006) (0)
The role of GSK3β in rapamycin-mediated cell cycle regulation (2005) (0)
Abstract 4122: The regulatory mechanism of PD-L1 level through ER-associated degradation (2019) (0)
Abstract 3032: Tazarotene-induced gene 1 promotes tumorigenicity and invasiveness of inflammatory breast cancer through receptor tyrosine kinase Axl. (2013) (0)
Advances in Experimental Medicine and Biology: Preface (2007) (0)
The p202 Gene as a Tumor Suppressor in Prostate Cancer Cells (2005) (0)
Abstract 3027: A novel function of EGFR in epigenetic modulation via hMOF in breast cancer . (2013) (0)
14-3-3 z TurnsTGF-b ’ s Func tion fromTumorSuppressor toMetastasis Promoter in Breast Cancer by Contextual Changes of Smad Partners from p 53 to Gli 2 Graphical (2015) (0)
Abstract LB097: MET inhibitor enhances efficacies of gemcitabine and olaparib in pancreatic cancer cells (2021) (0)
Abstract B02: Ephrin receptor A10 promotes PD-L1 expression for breast cancer immune evasion (2020) (0)
High level of STK-15 expression in primary breast tumors correlates with nuclear grade (2001) (0)
Erratum to 'Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma' [J Hepatol 2021 (907-918)]. (2022) (0)
Targeting HER-2/neu Overexpression By Suicide Ribozyme In Breast Cancer. (1997) (0)
Abstract 5606: Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1 (2018) (0)
Preparation and Characterization of Liposomal-Lipophilic Tumor Necrosis Factor 1 (2006) (0)
Rewired m6A epitranscriptomic networks link mutant p53 to neoplastic transformation (2023) (0)
DNA damage-induced paraspeckle formation enhances DNA repair and tumor radioresistance by recruiting ribosomal protein P0 (2022) (0)
Abstract LB-119: Single-cell live imaging of paclitaxel-resistant cancer cell generation (2016) (0)
PTEN self-regulates through USP11 via the PI3K-FOXO pathway to stabilize tumor suppression (2019) (0)
ivation of Murine Double Minute 2 by Akt in Mammary helium Delays Mammary Involution and R elerates Mammary Tumorigenesis (2010) (0)
Abstract LB-092: TKI insensitive role of EGFRconfers TKI resistance via PKCδ (2019) (0)
Dynamics of EGFR Trafficking from Membrane into Deep Cytoplasm Revealed by a Spatiotemporally Multiplexed 3D Tracking Microscope (2016) (0)
Suppression of mesenchymal phenotype in inflammatory breast cancer by EGFR tyrosine kinase inhibitor erlotinib: a novel approach to suppressing metastasis. (2009) (0)
612 Human ribonucleases act as potential plasma biomarkers for targeted therapy and immunotherapy in hepatocellular carcinoma (2021) (0)
Abstract B14: The novel function and trafficking mechanism of nuclear ErbB‐2 (2009) (0)
1 Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin-Cytosine Deaminase-Uracil Phosphoribosyl Transferase (2011) (0)
Abstract 120: Compartmentalized functions of epidermal growth factor receptor (EGFR) in tumorigenesis and malignant phenotypes (2021) (0)
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion (2018) (0)
Abstract AP21: A NOVEL TARGET FOR OVERCOMING ADAPTIVE RESISTANCE TO ANTI-ANGIOGENIC THERAPY IN OVARIAN CANCER (2019) (0)
Abstract 1051: EGFR inhibitors attenuate caspase-independent cell death and confer negative effects on cisplatin . (2013) (0)
IRG1/Itaconate induces metabolic reprogramming to suppress ER-positive breast cancer cell growth. (2023) (0)
The E1A Gene Therapy: A Two Way Translational Research (2002) (0)
Abstract B03: Cisplatin-resistant cells possess collateral sensitivity to folate antimetabolites (2015) (0)
AB001. Keynote. Development of effective immune checkpoint cancer therapy (2019) (0)
Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance (2021) (0)
Abstract 5854: TIE2-mediated epigenetic marks regulate therapeutic resistance of glioblastoma (2017) (0)
Structural insights into EphA4 unconventional activation from prediction of the EphA4 and its complex with ribonuclease 1. (2022) (0)
Abstract 5120: Using flow-proteometric platform to analyze individual signaling complexes in tumor tissue (2015) (0)
Abstract 1086: RHA plays an important role in EGFR-mediated gene transcription in cancer cells (2011) (0)
AberrantExpressionofproPTPRN 2 inCancerCells Confers Resistance to Apoptosis (2015) (0)
P202 AS A Potential Therapeutic Gene for Breast Cancer (2004) (0)
Therapeutic Discovery Targeted Expression of BikDDEliminates Breast Cancerwith Virtually No Toxicity in Noninvasive Imaging Models (2012) (0)
Abstract 5146: The histone demethylase KDM2A is a new promoter of tumorigenesis, drug target and negative prognostic biomarker for non-small cell lung cancer (2014) (0)
Epithelial-mesenchymal transition confers resistance to rapamycin (2011) (0)
Author Correction: CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer (2020) (0)
Abstract 1027: Inhibition of c-MET upregulates PD-L1 related immune escape in lung adenocarcinoma (2020) (0)
Determination of protein concentration with two-dimensional (2D) Photon burst diagrams using microfluidic channel (2008) (0)
Tumor suppression activity of adeno virus 5 el a in prostate cancer (1998) (0)
Immune checkpoint blockades therapy of melanoma. (2023) (0)
The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis (2020) (0)
Unfolded Protein Response Is Required in nu/nu Mice MicrovasculatureforTreatingBreastTumorwithTunicamycin * (2011) (0)
Detection of Gasdermin C-Mediated Cancer Cell Pyroptosis. (2023) (0)
Abstract 2784: Targeting TGF-β regulated E3 ligases: a novel therapeutic approach for primary liver cancer (2014) (0)
ADP-ribosylation inhibitors inhibit cellular RNA synthesis but do not affect expression of manganous superoxide dismutase or heat shock protein 70 in tumor necrosis factor alpha-sensitive and -resistant tumor cells. (1995) (0)
Therapeutics , Targets , and Chemical Biology De fi nition of PKC-a , CDK 6 , and MET as Therapeutic Targets in Triple-Negative Breast Cancer (2014) (0)
Abstract LB-258: EGFR and c-MET cooperate to enhance PARP inhibitor resistance in hepatocellular carcinoma (2019) (0)
Abstract 4713: Deubiquitination and stabilization of programmed cell death-ligand 1 by CSN5 (2017) (0)
Nardilysin-Regulated Scission Mechanism Activates Polo-like Kinase 3 to Suppress the Development of Pancreatic Cancer (2022) (0)
LncRNAs-directed PTEN enzymatic switch governs epithelial–mesenchymal transition (2019) (0)
Chemosensitization FOXO 3 a-Dependent Mechanism of E 1 A-Induced Updated (2011) (0)
266 POSTER Apoptosis induction in acute myeloid leukemia by inhibition of MEK and MDM2 is strongly associated with the BH3-only proteins Puma and Bim (2008) (0)
Abstract 3081: Secretory human ribonuclease 1 functions as Eph receptor A4 ligand to promote breast tumor initiation (2021) (0)
Translational research: E1A cancer gene therapy and β-catenin as a prognostic marker (2002) (0)
[abstract] Selective breast tumor growth suppression mediated by the enhanced breast cancer-specific promoter (2004) (0)

This paper list is powered by the following services:

Other Resources About Mien-Chie Hung

en.wikipedia.org

What Schools Are Affiliated With Mien-Chie Hung?

Mien-Chie Hung is affiliated with the following schools:

Mien-Chie Hung's Academic­Influence.com Rankings

Mien-Chie Hung's Degrees

Why Is Mien-Chie Hung Influential?

Mien-Chie Hung's Published Works

Published Works

Other Resources About Mien-Chie Hung

What Schools Are Affiliated With Mien-Chie Hung?

Mien-Chie Hung's AcademicInfluence.com Rankings